Dopamine Dorsolateral Prefrontal Cortex Behavioural Flexibility

NCT ID: NCT03068884

Last Updated: 2018-02-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

24 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-03-01

Study Completion Date

2018-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Behavioural or cognitive flexibility (BF) is an essential ability which allows an organism to adaptively change responses in accordance with feedback of results. In humans, this ability is disrupted among those who suffer a variety of neurological and psychiatric conditions including Parkinson's disease, schizophrenia, addiction, obsessive compulsive disorder and autism. Additionally, there is evidence of substantial individual differences in BF within the healthy population.

Two known neurobiological mechanisms which relate to BF performance are variation in dopamine (DA) and serotonin (SE) function. One particular brain regions which has been heavily implicated in BF is the prefrontal cortex (PFC), with the dorsolateral PFC receiving a largely DA innervation and the dorsomedial PFC a SE input. Studies have demonstrated that damage to parts of PFC including the orbitofrontal cortex (OFC), for example, impairs reversal learning (a form of BF) whereas lesions of the dorsolateral PFC affect attentional set-shifting (another measure of BF).

In humans, putative augmentation of DA efflux via administration of the DA and norepinephrine precursor tyrosine has been shown to improve task-switching performance, and inhibitory control suggesting a causal role of DA in regulating BF. Similarly, putative depletion of serotonin neurotransmission via tryptophan depletion procedures has been shown to reduce the BOLD response during performance monitoring and increase perseverative behaviour.

One important strategy (in humans) to observe whether the PFC is causally involved in BF performance, is by reversible electrical stimulation of the PFC, so that PFC cells could be inhibited or excited while a participant is performing a BF task. In recent years, several laboratories have taken advantage of a relatively new technology known as transcranial direct current stimulation (tDCS) to study the relationship between brain function and behaviour. Using this technique, increases or decreases in cortical excitability are partly determined by the polarity of the stimulation; increases occur under the anode electrode whereas decreases occur under the negatively charged cathode.

Using this approach, several studies have shown that anodal and cathodal stimulation over the PFC can have a number of effects on BF performance, with general improvements during anodal stimulation and impairments during cathodal. If this is the case, one important step that remains to be understood is whether dopamine and serotonin are causally related to these outcomes when neurons of the dLPFC/dMPFC are either excited or inhibited via tDCS.

Thus, the specific novelty of this study rests in combining a psychopharmacological approach (i.e. tyrosine/tryptophan loading) with selective neuroanatomical (i.e. dorsolateral/dorsomedial prefrontal cortex) inhibition of cells via tDCS while participants are performing BF tasks. By doing so, we will be able to establish whether increased dopaminergic/serotonergic output to the PFC is a necessary requirement for BF performance.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cognitive Change

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Tdcs sham

Group Type SHAM_COMPARATOR

L-Tyrosine

Intervention Type DIETARY_SUPPLEMENT

Administration of 2 grams tyrosine

Cellulose (placebo)

Intervention Type DIETARY_SUPPLEMENT

Administration of 2 grams cellulose

Placebo

Group Type PLACEBO_COMPARATOR

Cathodal Transcranial direct current stimulation

Intervention Type DEVICE

Cathodal transcranial direct current stimulation over the dorsolateral prefrontal cortex

Transcranial direct current stimulation (sham)

Intervention Type DEVICE

Sham tDCS

Tdcs cathodal

Group Type EXPERIMENTAL

L-Tyrosine

Intervention Type DIETARY_SUPPLEMENT

Administration of 2 grams tyrosine

Cellulose (placebo)

Intervention Type DIETARY_SUPPLEMENT

Administration of 2 grams cellulose

Tyrosine

Group Type EXPERIMENTAL

Cathodal Transcranial direct current stimulation

Intervention Type DEVICE

Cathodal transcranial direct current stimulation over the dorsolateral prefrontal cortex

Transcranial direct current stimulation (sham)

Intervention Type DEVICE

Sham tDCS

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cathodal Transcranial direct current stimulation

Cathodal transcranial direct current stimulation over the dorsolateral prefrontal cortex

Intervention Type DEVICE

L-Tyrosine

Administration of 2 grams tyrosine

Intervention Type DIETARY_SUPPLEMENT

Transcranial direct current stimulation (sham)

Sham tDCS

Intervention Type DEVICE

Cellulose (placebo)

Administration of 2 grams cellulose

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Aged between 18 and 30 years
* In good health
* Agrees to fast overnight prior to testing

Exclusion Criteria

* Presence of cardiac, hepatic, renal, or neurological disorders
* Presence of damaged or diseased skin on your face and scalp, or a sensitive scalp
* A history of alcohol or drug addiction, or severe psychiatric illness
* Taking drugs which may lower seizure threshold (i.e. epilepsy)
* In a state of pregnancy
* Having slept less than 6 hours the night before testing
* A history of migraine or headaches
* A history of taking antidepressants
* A history of taking tyrosine supplements
Minimum Eligible Age

18 Years

Maximum Eligible Age

30 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Sheffield Hallam University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Luca Aquili, Ph.D.

Role: PRINCIPAL_INVESTIGATOR

Sheffield Hallam University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Psychology laboratories

Sheffield, Yorkshire, United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United Kingdom

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

SheffieldHallamAquili2017

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Dopamine and Brain Computer Interface
NCT06729658 COMPLETED EARLY_PHASE1
Dopaminergic Dysfunction in Late-Life Depression
NCT04469959 ACTIVE_NOT_RECRUITING PHASE2
tDCS on Parkinson's Disease Cognition
NCT03025334 RECRUITING NA